| Source | Evidence on protein | Close homologs |
|---|---|---|
| Cuervo et al. | no | yes: 0 |
| Hassani et al. | no | yes: 0 |
| Forrest at al. (metacyclic) | no | yes: 0 |
| Forrest at al. (procyclic) | no | yes: 0 |
| Silverman et al. | no | yes: 0 |
| Pissara et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| Pires et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| Silverman et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| Jamdhade et al. | no | yes: 0 |
| Source | Evidence on protein | Close homologs |
|---|---|---|
| DeepLoc | ||
| SignalP6 | no | yes: 0, no: 5 |
| NetGPI | no | yes: 0, no: 5 |
Related structures:
AlphaFold database: A4H338
| Leishmania | From | To | Domain/Motif | Score |
|---|---|---|---|---|
| CLV_NRD_NRD_1 | 120 | 122 | PF00675 | 0.472 |
| CLV_NRD_NRD_1 | 172 | 174 | PF00675 | 0.394 |
| CLV_NRD_NRD_1 | 75 | 77 | PF00675 | 0.449 |
| CLV_PCSK_KEX2_1 | 120 | 122 | PF00082 | 0.472 |
| CLV_PCSK_KEX2_1 | 2 | 4 | PF00082 | 0.588 |
| CLV_PCSK_KEX2_1 | 75 | 77 | PF00082 | 0.411 |
| CLV_PCSK_PC1ET2_1 | 2 | 4 | PF00082 | 0.568 |
| CLV_PCSK_SKI1_1 | 177 | 181 | PF00082 | 0.453 |
| CLV_PCSK_SKI1_1 | 67 | 71 | PF00082 | 0.441 |
| DEG_Nend_UBRbox_1 | 1 | 4 | PF02207 | 0.575 |
| DEG_SCF_FBW7_1 | 48 | 55 | PF00400 | 0.371 |
| DEG_SPOP_SBC_1 | 33 | 37 | PF00917 | 0.539 |
| DOC_CYCLIN_RxL_1 | 63 | 72 | PF00134 | 0.336 |
| DOC_MAPK_DCC_7 | 121 | 131 | PF00069 | 0.453 |
| DOC_MAPK_gen_1 | 105 | 113 | PF00069 | 0.446 |
| DOC_MAPK_gen_1 | 120 | 126 | PF00069 | 0.361 |
| DOC_MAPK_gen_1 | 173 | 182 | PF00069 | 0.458 |
| DOC_MAPK_MEF2A_6 | 173 | 182 | PF00069 | 0.458 |
| DOC_USP7_MATH_1 | 16 | 20 | PF00917 | 0.521 |
| DOC_USP7_MATH_1 | 33 | 37 | PF00917 | 0.539 |
| DOC_USP7_MATH_1 | 9 | 13 | PF00917 | 0.530 |
| DOC_WW_Pin1_4 | 29 | 34 | PF00397 | 0.532 |
| DOC_WW_Pin1_4 | 48 | 53 | PF00397 | 0.432 |
| LIG_14-3-3_CanoR_1 | 177 | 183 | PF00244 | 0.446 |
| LIG_14-3-3_CanoR_1 | 3 | 8 | PF00244 | 0.555 |
| LIG_Clathr_ClatBox_1 | 39 | 43 | PF01394 | 0.473 |
| LIG_FHA_1 | 18 | 24 | PF00498 | 0.582 |
| LIG_FHA_1 | 49 | 55 | PF00498 | 0.362 |
| LIG_LIR_Apic_2 | 43 | 48 | PF02991 | 0.461 |
| LIG_SH2_NCK_1 | 45 | 49 | PF00017 | 0.447 |
| LIG_SH2_SRC | 45 | 48 | PF00017 | 0.482 |
| LIG_SH2_STAT5 | 158 | 161 | PF00017 | 0.464 |
| LIG_SUMO_SIM_par_1 | 34 | 44 | PF11976 | 0.471 |
| LIG_TRAF2_1 | 115 | 118 | PF00917 | 0.454 |
| LIG_TRAF2_1 | 41 | 44 | PF00917 | 0.606 |
| MOD_CK1_1 | 19 | 25 | PF00069 | 0.631 |
| MOD_CK1_1 | 26 | 32 | PF00069 | 0.554 |
| MOD_CK1_1 | 34 | 40 | PF00069 | 0.550 |
| MOD_CK2_1 | 11 | 17 | PF00069 | 0.643 |
| MOD_Cter_Amidation | 159 | 162 | PF01082 | 0.464 |
| MOD_GlcNHglycan | 13 | 16 | PF01048 | 0.575 |
| MOD_GlcNHglycan | 25 | 28 | PF01048 | 0.489 |
| MOD_GlcNHglycan | 7 | 10 | PF01048 | 0.641 |
| MOD_GlcNHglycan | 77 | 80 | PF01048 | 0.339 |
| MOD_GSK3_1 | 17 | 24 | PF00069 | 0.595 |
| MOD_GSK3_1 | 29 | 36 | PF00069 | 0.444 |
| MOD_GSK3_1 | 48 | 55 | PF00069 | 0.381 |
| MOD_GSK3_1 | 5 | 12 | PF00069 | 0.591 |
| MOD_NEK2_1 | 23 | 28 | PF00069 | 0.644 |
| MOD_PIKK_1 | 94 | 100 | PF00454 | 0.408 |
| MOD_PKA_1 | 75 | 81 | PF00069 | 0.473 |
| MOD_PKA_2 | 104 | 110 | PF00069 | 0.446 |
| MOD_PKA_2 | 119 | 125 | PF00069 | 0.554 |
| MOD_PKA_2 | 75 | 81 | PF00069 | 0.473 |
| MOD_PKB_1 | 3 | 11 | PF00069 | 0.582 |
| MOD_Plk_4 | 35 | 41 | PF00069 | 0.687 |
| MOD_Plk_4 | 52 | 58 | PF00069 | 0.387 |
| MOD_ProDKin_1 | 29 | 35 | PF00069 | 0.531 |
| MOD_ProDKin_1 | 48 | 54 | PF00069 | 0.427 |
| TRG_DiLeu_BaLyEn_6 | 49 | 54 | PF01217 | 0.434 |
| TRG_ER_diArg_1 | 74 | 76 | PF00400 | 0.452 |
| TRG_Pf-PMV_PEXEL_1 | 114 | 118 | PF00026 | 0.399 |
| TRG_Pf-PMV_PEXEL_1 | 5 | 10 | PF00026 | 0.510 |
| TRG_Pf-PMV_PEXEL_1 | 67 | 72 | PF00026 | 0.309 |
| Protein | Taxonomy | Sequence identity | Coverage |
|---|---|---|---|
| A0A0N1I8D7 | Leptomonas seymouri | 53% | 100% |
| A0A451EJ62 | Leishmania donovani | 81% | 100% |
| E9ABZ3 | Leishmania major | 82% | 100% |
| E9AJ90 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 81% | 100% |